Cooper Companies has announced its financial guidance for fiscal year 2025, forecasting a significant earnings per share (EPS) growth of 10% to 11.5%. The company's non-GAAP diluted EPS is expected to range between $3.94 and $4.02, marking a noticeable increase from the previous year. This optimistic outlook is part of the company's broader strategy to boost its financial performance in the coming year.

In addition to anticipated EPS growth, Cooper Companies has set robust revenue projections for its segments. The total revenue is expected to lie between $4.08 billion and $4.16 billion, showcasing an organic growth of 6% to 8%. Specifically, the CooperVision segment is projected to achieve revenues between $2.73 billion and $2.79 billion with an organic growth rate of 6.5% to 8.5%. Meanwhile, the CooperSurgical segment expects to bring in $1.35 billion to $1.37 billion, reflecting a growth of 4% to 6%. Reuters highlighted the company's aggressive push in its myopia management initiatives, with sales from its MiSight product anticipated to grow by approximately 40% this year.

Cooper Companies is strategically focused on expanding its presence in the growing contact lens market, which is expected to rise by 5% to 7% in 2025. The company aims to enhance its market share through innovative product offerings. This approach is supported by their initiatives in the myopia management portfolio and revenue expansions across key segments.